Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Schizophr Res. 2010 Apr 24;122(1-3):248–256. doi: 10.1016/j.schres.2010.03.025

Fig. 2. Dose-response relationship between topical methylnicotinate concentration and cutaneous blood flow response.

Fig. 2

Data are expressed as mean ± SD from 20 control subjects and 20 patients with schizophrenia.

*There is a significant rightward shift and lower asymptote of the curve from the schizophrenia group.